ACCEL Lite: ESC Congress 2021 Late Breaker: EMPEROR-Preserved

In this interview, Jeroen Bax, PhD, MD, FACC; Stefan Anker, MD, PhD; and Sherry-Ann Brown, MD, PhD, FACC, discuss the ESC Congress 2021 late breaker EMPEROR-Preserved, which evaluates the effect of empagliflozin for risk of cardiovascular death and hospitalisation for patients with heart failure and a preserved fraction with and without diabetes.

Like what you hear? ACCEL Subscribers enjoy 20+ insider interviews like these every month, with CME/MOC credit and other exclusive benefits. Subscribe today for more, and check out what's new at www.acc.org/ACCEL.




Clinical Topics: Arrhythmias and Clinical EP, Cardiovascular Care Team, Diabetes and Cardiometabolic Disease, Geriatric Cardiology, Heart Failure and Cardiomyopathies, Prevention, Atrial Fibrillation/Supraventricular Arrhythmias, Acute Heart Failure, Heart Failure and Cardiac Biomarkers

Keywords: ACCELLite, ESC21, ESC Congress, Atrial Fibrillation, Diabetes Mellitus, Type 2, Diuretics, Geriatrics, Glomerular Filtration Rate, Heart Failure, Metabolic Syndrome, Natriuretic Peptide, Brain, Prediabetic State, Renal Insufficiency, Secondary Prevention, Stroke Volume, Ventricular Function, Left


< Back to Listings